Indicated for: HIV-1 infection
Route of administration: oral
Substance: emtricitabine + tenofovir disoproxil (nucleoside/nucleotide reverse transcriptase inhibitor + antiretroviral)
ATC: J05AR03 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
The combination of emtricitabine and tenofovir disoproxil is used for the treatment of HIV infection and for pre-exposure prophylaxis (PrEP). It works by inhibiting reverse transcriptase, preventing HIV replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, diarrhea, headaches, and decreased bone mineral density.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal function and bone density.
This medication is an effective option for managing HIV infection and preventing virus transmission, helping to improve patients' quality of life.
NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment
Price
Copayment
Patient
281.71 RON
281.71 RON
0.00 RON